MBIO - Mustang Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.2800
+0.1700 (+4.14%)
As of 1:10PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.1100
Open4.1200
Bid4.2500 x 3000
Ask4.3100 x 800
Day's Range4.1000 - 4.2900
52 Week Range2.1800 - 10.2000
Volume84,560
Avg. Volume289,292
Market Cap173.222M
Beta (3Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)-1.3250
Earnings DateAug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.25
Trade prices are not sourced from all markets
  • GlobeNewswire

    Mustang Bio to Present at Scientific Conferences in September 2019

    NEW YORK, Sept. 09, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in.

  • Mustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution
    PR Newswire

    Mustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution

    Pipeline and Clinical Trials Focused on Cancers and Genetic Disorders BOTHELL, Wash. , Sept. 3, 2019 /PRNewswire/ --   BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio ...

  • GlobeNewswire

    Mustang Bio to Present at September 2019 Investor Conferences

    NEW YORK, Aug. 29, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • GlobeNewswire

    Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity™ Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it has entered into a license agreement with CSL Behring for the Cytegrity™ stable producer cell line developed and used by St. Jude Children’s Research Hospital (“St. Jude”). Cytegrity™ stable producer cell line will be used to produce the viral vector for Mustang Bio’s MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency (XSCID).

  • GlobeNewswire

    Mustang Bio and St. Jude Children’s Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency (XSCID) granted regenerative medicine advanced therapy (RMAT) designation from FDA

    Mustang Bio, Inc. (MBIO) and St. Jude Children’s Research Hospital have announced that MB-107, a lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency, also known as bubble boy disease, has been granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA). Mustang, a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, and St. Jude, the nation’s leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases, established a partnership to continue development of the lentiviral gene therapy in August 2018.

  • GlobeNewswire

    Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases

    NEW YORK, Aug. 13, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • GlobeNewswire

    Mustang Bio to Present at 11th Annual Bioprocessing Summit

    NEW YORK, Aug. 12, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • GlobeNewswire

    Mustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, Aug. 09, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • GlobeNewswire

    FDA Clears IND for Mustang Bio’s MB-102 (CD123 CAR T)

    NEW YORK, Aug. 05, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • GlobeNewswire

    Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Acute Myeloid Leukemia

    NEW YORK, July 24, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • The Mustang Bio (NASDAQ:MBIO) Share Price Is Down 52% So Some Shareholders Are Wishing They Sold
    Simply Wall St.

    The Mustang Bio (NASDAQ:MBIO) Share Price Is Down 52% So Some Shareholders Are Wishing They Sold

    While it may not be enough for some shareholders, we think it is good to see the Mustang Bio, Inc. (NASDAQ:MBIO) share...

  • GlobeNewswire

    Mustang Bio and St. Jude Children’s Research Hospital to Participate in Panel Discussion at Boston CEO 2019

    NEW YORK, and MEMPHIS, Tenn., May 23, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical.

  • GlobeNewswire

    Mustang Bio and Nationwide Children’s Hospital Receive Orphan Drug Designation for MB-108 (Oncolytic Virus C134) for the Treatment of Malignant Glioma

    NEW YORK and COLUMBUS, Ohio, May 16, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical.

  • GlobeNewswire

    Mustang Bio to Present at the Cell & Gene Therapy USA Congress 2019

    NEW YORK, May 13, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • GlobeNewswire

    Mustang Bio Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

    NEW YORK, May 10, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell.

  • GlobeNewswire

    Mustang Bio Announces Full Exercise of Option

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the underwriters of its recent public offering of common stock have exercised in full their option and purchased an additional 1,031,250 shares at the public offering price of $4.00 per share.

  • GlobeNewswire

    Mustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that City of Hope, a world-renowned independent cancer research and treatment center, has begun enrolling patients with relapsed or treatment-resistant multiple myeloma in an innovative CS1 chimeric antigen receptor (CAR) T cell therapy (MB-104) trial.

  • GlobeNewswire

    Mustang Bio Announces Pricing of Public Offering of Common Stock

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced the pricing of its previously announced underwritten public offering. Mustang is offering 6,875,000 shares of its common stock, par value $0.0001 per share, at a price to the public of $4.00 per share. In connection with the offering, Mustang has also granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of common stock offered in the public offering, at the same public offering price per share, to cover over-allotments, if any.

  • Benzinga

    The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Stock In Focus G1 Therapeutics Plans Regulatory Submission For Bone Marrow Preservation Drug G1 Therapeutics Inc (NASDAQ: ...

  • GlobeNewswire

    Mustang Bio Announces Proposed Public Offering of Common Stock

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Mustang expects to grant the underwriters a 30‐day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering.

  • ACCESSWIRE

    FDA Events Put Healthcare Stocks In The Headlines: Here's One That No One's Talking About Yet

    - Biotech and healthcare stocks are loved by traders for their big price moves, which can happen when a company makes progress (or faces problems) with their developmental products like drugs and devices. Results from Phase I, II and III clinical studies, and FDA or European approvals (and rejections), can send stocks into the headlines. Recent examples include Mustang Bio (MBIO) and Akari Therapeutics (AKTX) with their respective human study results.

  • Is Mustang Bio the Next Great Biotech Stock?
    InvestorPlace

    Is Mustang Bio the Next Great Biotech Stock?

    Do you remember the movie The Boy in the Plastic Bubble starring John Travolta? How about Bubble Boy starring Jake Gyllenhaal? Both were about a child born without an immune system, forced to live in a bubble to avoid contamination from the outside world.Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsWell, now, Mustang Bio (NASDAQ:MBIO) has cured eight infants suffering from the "Bubble Boy" immune disorder, sending MBIO stock up as high as $10.20 in pre-Good Friday trading. The question investors are asking themselves today is whether they should get in on the action before it's too late. FOMO is alive and well and living in this micro-cap biotechnology stock. Why MBIO Stock Is a Good Speculative BetAny time a biotech company comes up with a gene therapy that works, there's bound to be excitement surrounding it. Even better if the infants suffered few, if any, side effects from the experimental gene therapy.Mustang Bio is a 2015 spinoff of Fortress Biotech (NASDAQ:FBIO), a company that is run by Lindsay Rosenwald and Michael Weiss, two serial healthcare entrepreneurs, who've spread lots of bets on small companies like Mustang Bio, of which Fortress owns approximately 38%. * 10 High-Yielding Dividend Stocks That Won't Wilt "While I am a biotech entrepreneur, I am also a 'risk manager,' as we have many shots on goal for such small companies," Rosenwald said in an email. "The more shots on goal, theoretically the less risk there is."However, despite the success of the gene therapy to date, it likely won't file for FDA approval until late 2021 or beyond. In the meantime, it's little to no money in -- 2018 income of $561,000 from interest on its cash on hand -- and $31.2 million in operating expenses, such as research and development, out. So, it's likely to burn through $100 million in operating losses before it even files with the FDA. While this might seem like an argument as to why MBIO stock is not a good speculative bet, it's counter-intuitive. Mustang Bio had cash and short-term investments of $61 million at the end of 2017. At the end of 2018, it was down to $34 million, a reduction of around $29 million, not too far off the operating losses for the year. The company announced on March 29, a $20 million venture debt financing agreement at 9% plus the amount by which the one month LIBOR rate exceeds 2.5%. It's currently at 2.48%. With interest rates stalled and possibly heading lower if a recession rears its ugly head, it looks like Mustang Bio's on the hook for about $1.8 million in interest on the loan.That gets it to $54 million on the balance sheet, close to two years worth of operating losses and into 2021. At that point, should everything about MB-107 remain positive, Mustang Bio will have plenty of financing options to get itself through the next two years, including issuing some more MBIO stock. As speculative biotech plays go, Mustang Bio seems like a good one. Why It's NotWhen it comes to biotech investing, there's no sure thing. The company still needs to confirm the benefits of a handful of patients who've received the experimental gene therapy. Those patients could fail to benefit from MB-107, as the others did. In 2020, Mustang Bio takes over the trial program from St. Jude Children's Research Hospital, which is licensing the gene therapy to the company. It's possible, but unlikely, that something could go wrong from a clinical perspective once the trial is in Mustang Bio's hands. However, CEO Manny Litchman doesn't think so. "The data are extraordinary for every single patient," Litchman said. "It's that compelling nature of the data, in particular for those who don't have a matched sibling donor, that we believe will convince the FDA to do this. Of course, just as in life, we don't always get what we want. The FDA could say no to Mustang Bio and then it's back to the drawing board after more than $150 million in losses. The Bottom Line on Mustang Bio StockI'm not a big believer in investing in money-losing companies. However, as Fortress' Rosenwald said, you've got to take a lot of shots in biotech to be successful. The same goes for biotech investing. * Verizon 5G Launch: 12 Things We Know If you can afford to lose your entire investment, I wouldn't see a problem putting down a small wager on MBIO stock. While you're at it, you might put a small amount in Fortress as well to spread your bets and all that cautionary advice. At the time of this writing, Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post Is Mustang Bio the Next Great Biotech Stock? appeared first on InvestorPlace.

  • Mustang Bio News: MBIO Stock Skyrockets on New ‘Bubble Boy’ Therapy
    InvestorPlace

    Mustang Bio News: MBIO Stock Skyrockets on New ‘Bubble Boy’ Therapy

    Mustang Bio news concerning a trial about a new gene therapy for treating "bubbly boy" disease has MBIO stock soaring on Thursday.Source: Shutterstock Mustang Bio (NASDAQ:MBIO) notes that a Phase1/2 clinical trial of a gene therapy to treat XSCID, which is also known as SCID-X1. This therapy results in children not having a proper immune system and being unable to fight off illnesses.According to the Mustang Bio news release, a lentiviral gene therapy was used on infants under two years of age with the bubble boy disease. There are currently 10 infants that have gone through this therapy and the recent results come from eight of those patients.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMustang Bio has found that the lentiviral gene therapy has been a success for the eight patients tracked in the study. These eight patients saw a successful transferring of a normal copy of the IL2RG gene to bone marrow stem cells.All eight of the patients in the study have cleared their previous infections and are now growing normally. Seven of the eight saw CD3+, CD4+ and CD4+ naive T-cell and natural killer normalization within three to four months after treatment. The eighth infant initially had insufficient T cells, but has now normalized. * 5 Dividend Stocks Perfect for Retirees "The results have been very good thus far. We've been able to restore a full immune system pretty quickly," Ewelina Mamcarz, M.D., said in a statement. "All of these patients were able to come off of isolation and they've returned home with immune systems that were fully functional."MBIO stock was up 128% as of noon Thursday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Dividend Stocks Perfect for Retirees * 7 Reasons the Stock Market Rally Isn't Over Yet * 10 S&P 500 Stocks to Weather the Earnings Storm As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Mustang Bio News: MBIO Stock Skyrockets on New 'Bubble Boy' Therapy appeared first on InvestorPlace.

  • Why Mustang Bio Stock Is On Fire Today
    Motley Fool

    Why Mustang Bio Stock Is On Fire Today

    A new gene therapy could be a functional cure for "bubble boy" disease.